NIH-CPSINational Institutes of Health Chronic Prostatitis Symptom Index
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The average of total NIH-CPSI score was calculated as 9.08 (distribution of 1-40) according to the subgroups of pain (0-21 points), quality of life (0-12 points), and urinary symptoms (0-10 points) (Table 1).
The NIH-CPSI severity was categorized as mild (0-15 points), moderate (16-29 points), and severe (>29 points) dysfunction with 134 (60%), 67 (30%), and 22 (10%) patients in each group, respectively.
Results showed an improvement in NIH-CPSI pain and quality of life categories for all patients who received previous orchialgia treatment.
Hence, our study intended to explore the prevalence of PLS and outcomes of NIH-CPSI scores in outpatients with LPE and APE (Table 2).
Total NIH-CPSI scores for 92.5% of the participants (86 of 93) declined by over 50% from baseline.
A recent randomized, double-blind trial was slightly more encouraging, with 47% of men reporting at least a 6-point decrease in their NIH-CPSI total score after 6 weeks of pregabalin, compared with 36% of those given placebo.
Baseline characteristics of the groups were similar for age, race, prostate size, median quality of life scores, and median NIH-CPSI pain domain scores.
At the baseline assessment, patients were evaluated for NIH-CPSI, NIH-CPSI-based pain and QoL scores, PV (mL), and uroflowmetry ([Q.sub.max],) mL/s.
(20) As a check on generalizability, primary comparisons between the online and clinic data were computed for age and domains of NIH-CPSI (quality of life pain, urinary), and the PHQ-9.
Use of the NIH-CPSI is important in that it affords patients the opportunity to tell their physician how severe they perceive their pain or symptoms to be.
Prevalence of prostatitis-like symptoms in a population based study employing the NIH-chronic prostatitis symptom index (NIH-CPSI).
Differences between pre/post-treatment NIH-CPSI Total and domain scores were computed with repeated measures ANOVAs.